Recent studies have shown that by improving the linking technology and developing novel drug carriers, ADCs can more effectively kill cancer cells while reducing damage to healthy cells. Antibody-Drug Conjugates (ADCs), as a new anticancer therapy, have attracted wide attention in the field of biomedicine in recent years. By linking powerful anticancer drugs with specific antibodies, ADCs can deliver the drugs directly to cancer cells, maximizing efficacy while minimizing damage to normal cells